Sparfosic acid

Drug Profile

Sparfosic acid

Alternative Names: CI 882; N-phosphonacetyl-L-aspartate; N-phosphonacetyl-L-aspartic acid; NSC 224131; PALA; Sparfosate sodium

Latest Information Update: 24 Jan 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action Aspartate carbamoyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Hepatitis B; Respiratory syncytial virus infections

Most Recent Events

  • 24 Jan 2003 Discontinued - Preclinical for Hepatitis B in Australia (unspecified route)
  • 24 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
  • 15 Nov 2000 Preclinical development for Hepatitis B in Australia (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top